Abstract:Background: Tuberculosis is an infectious disease caused by Mycobacterium tuber-culosis. The current treatment protocols for pulmonary tuberculosis are quite effective, even though the treatment requires 3-6 months. The current treatment protocols for extrapulmonary tuberculosis are based on the same drugs that are used for pulmonary tuberculosis. However, the success rates are much lower for certain types of extrapulmonary tuberculosis, such as tubercu-lous meningitis. Tuberculous meningitis is one of the very few diseases attributable to bacteria that have a very high short-term mortality rate among diagnosed patients, even after treatment with antibiotics that are effective for pulmonary tuberculosis. For example, rifampicin is highly effective for the treatment of pulmonary tuberculosis, but its effectiveness for the treatment of tuberculous meningitis is much lower. The reason for the lower effectiveness of rifampicin against tuberculous meningitis is that it has low Blood-Brain Barrier (BBB) permeability, which results in lower concentrations of the drug at the required sites in the central nervous system. Methods: In this work, ligands having increased BBB permeability and pharmacokinetic and pharmacodynamic properties, either similar to or better than that of rifampicin, have been de-signed. The BBB permeability of the designed molecules was assessed by using pkCSM, a ma-chine-learning model. Pharmacokinetic properties, drug-likeness, and synthesizability were as-sessed by using SWISS-MODEL. The binding affinity of the designed drugs was assessed by using AutoDock Vina. A customized scoring function, StWN score, was used for a quantitative weighted assessment of all the properties of interest to rank the designed molecules. Results: In this study, drug-like ligands have been designed that have been predicted to have high BBB permeability as well as high affinity for RNA polymerase β of Mycobacterium tuberculosis. Conclusion: The best ligands generated by the tools employed were selected as potential drugs to address the current need for better options for the treatment of tuberculous meningitis.

[New Inhibitors Targeting Bacterial RNA Polymerase].

Structural Basis of Mycobacterium Tuberculosis Transcription and Transcription Inhibition

Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles

Novel Rapidly Diversifiable Antimicrobial RNA Polymerase Switch Region Inhibitors with Confirmed Mode of Action in Haemophilus Influenzae.

Biochemical characterization of Mycobacterial RNA polymerases

Design of RNA Polymerase Inhibitors as Therapeutics for Tuberculous Meningitis

Inhibition of Bacterial RNA Polymerase Function and Protein-Protein Interactions: A Promising Approach for Next-Generation Antibacterial Therapeutics

Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis

The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase

Uncovering the Resistance Mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective.

Antibiotic Drugs Targeting Bacterial RNAs

Nα‐aroyl‐N‐aryl‐phenylalanine amides: a promising class of antimycobacterial agents targeting the RNA polymerase

Discovery of Inhibitors Targeting Protein-Protein Interaction between Bacterial RNA Polymerase and NusG as Novel Antimicrobials

Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events

Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction

Identification of echinoderm metabolites as potential inhibitors targeting wild-type and mutant forms of Escherichia coli RNA polymerase (RpoB) for tuberculosis treatment

Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance

New molecular insights into the tyrosyl-tRNA synthase inhibitors: CoMFA, CoMSIA analyses and molecular docking studies.

The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site

Probing the Molecular Mechanism of Rifampin Resistance Caused by the Point Mutations S456L and D441V on Mycobacterium Tuberculosis RNA Polymerase Through Gaussian Accelerated Molecular Dynamics Simulation.

Research Advances of Aminoacyl-tRNA Synthetase Inhibitors As Novel Anti-infective Agents